Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A2 mass in type 2 diabetes mellitus: Relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity

European Journal of Internal Medicine

Volumn 23, Issue 7, 2012, Pages 633-638

  Constantinides, Alexander ^a   De Vries, Rindert ^a   Van Leeuwen, Jeroen J J ^a   Gautier, Thomas ^b   Van Pelt, L Joost ^a   Tselepis, Alexandros D ^c   Lagrost, Laurent ^b   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Institut Médical de Génétique et d Immunologie   (France)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Bezafibrate; High sensitive C reactive protein; Lipoprotein associated phospholipase A2; Low density lipoprotein electronegativity; Simvastatin; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; BEZAFIBRATE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHOSPHOLIPASE A2; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BEZAFIBRATE; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SIMVASTATIN; TRIGLYCERIDES;

EID: 84865693944     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.05.008     Document Type: Article

References (37)

1. M.J. Caslake, and C.J. Packard Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke Nat Clin Pract Cardiovasc Med 2 2005 529 535
2. C.C. Tellis, and A.D. Tselepis The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma Biochim Biophys Acta 1791 2009 327 338
3. 2: a new target for statin therapy Curr Atheroscler Rep 12 2010 29 33
4. 2 in inflammation and atherosclerosis J Am Coll Cardiol 59 2012 764 772
5. A.D. Tselepis, C. Dentan, S.-A. Karabina, M.J. Chapman, and E. Ninio PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VLDL-1 in human plasma: catalytic characteristics and relation to the monocyte-derived enzyme Arterioscler Thromb Vasc Biol 15 1995 1764 1773
6. S. Benítez, J.L. Sánchez-Quesada, V. Ribas, O. Jorba, F. Blanco-Vaca, and F. González-Sastre Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction Circulation 108 2003 92 96
7. J.W. Gaubatz, B.K. Gillard, J.B. Massey, R.C. Hoogeveen, M. Huang, and E.E. Lloyd Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2) J Lipid Res 48 2007 348 357
8. T. Kujiraoka, T. Iwasaki, M. Ishihara, M. Ito, M. Nagano, and A. Kawaguchi Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus J Lipid Res 44 2003 2006 2014
9. C.J. Packard, D.S. O'Reilly, M.J. Caslake, A.D. McMahon, I. Ford, and J. Cooney Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group N Engl J Med 343 2000 1148 1155
10. M. Persson, G. Berglund, J.J. Nelson, and B. Hedblad Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden Atherosclerosis 200 2008 191 198
11. Lp-PLA(2) Studies Collaboration A. Thompson, P. Gao, L. Orfei, S. Watson, and E. Di Angelantonio Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
12. I.J. Hatoum, F.B. Hu, J.J. Nelson, and E.B. Rimm Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes Diabetes 59 2010 1239 1243
13. E.R. Mohler III, C.M. Ballantyne, M.H. Davidson, M. Hanefeld, L.M. Ruilope, and J.L. Johnson The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 29 2008 1632 1641
14. V. Tsimihodimos, S.A. Karabina, A.P. Tambaki, E. Bairaktari, J.A. Goudevenos, and M.J. Chapman Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB Arterioscler Thromb Vasc Biol 22 2002 306 311
15. M.A. Albert, R.J. Glynn, R.L. Wolfert, and P.M. Ridker The effect of statin therapy on lipoprotein associated phospholipase A2 levels Atherosclerosis 182 2005 193 198
16. M. O'Donoghue, D.A. Morrow, M.S. Sabatine, S.A. Murphy, C.H. McCabe, and C.P. Cannon Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial Circulation 113 2006 1745 1752
17. E.J. Schaefer, J.R. McNamara, B.F. Asztalos, T. Tayler, J.A. Daly, and J.L. Gleason Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects Am J Cardiol 95 2005 1025 1032
18. B. Ky, A. Burke, S. Tsimikas, M.L. Wolfe, M.G. Tadesse, and P.O. Szapary The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans J Am Coll Cardiol 51 2008 1653 1656
19. I.K. Karalis, S.C. Bergheanu, R. Wolterbeek, G.M. Dallinga-Thie, H. Hattori, and A. van Tol Effect of increasing doses of rosuvastatin and atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters Curr Med Res Opin 26 2010 2301 2313
20. J.B. Muhlestein, H.T. May, J.R. Jensen, B.D. Horne, R.B. Lanman, and F. Lavasani The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study J Am Coll Cardiol 48 2006 396 401
21. S.K. Ryu, Z. Mallat, J. Benessiano, A. Tedgui, A.G. Olsson, and W. Bao Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes Circulation 125 2012 757 766
22. V.G. Saougos, A.P. Tambaki, M. Kalogirou, M. Kostapanos, I.F. Gazi, and R.L. Wolfert Differential effect of hypolipidemic drugs on lipoprotein- associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2007 2236 2243
23. M.H. Davidson, M.W. Rooney, J. Drucker, H. Eugene Griffin, S. Oosman, and M. Bechert Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study Clin Ther 31 2009 2824 2838
24. V. Tsimihodimos, A. Kakafika, A.P. Tambaki, E. Bairaktari, M.J. Chapman, and M. Elisaf Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins J Lipid Res 44 2003 927 934
25. A.M. Wägner, J.L. Sánchez-Quesada, S. Benítez, C. Bancells, J. Ordóñez-Llanos, and A. Pérez Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study Diabetes Res Clin Pract 93 2011 e25 e28
26. S. Benítez, A. Pérez, J.L. Sánchez-Quesada, A.M. Wagner, M. Rigla, and R. Arcelus Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control Diabetes Metab Res Rev 23 2007 26 34
27. A.P. Mello, I.T. da Silva, D.S. Abdalla, and N.R. Damasceno Electronegative low-density lipoprotein: origin and impact on health and disease Atherosclerosis 215 2011 257 265
28. A. Constantinides, L.J. van Pelt, J.J. van Leeuwen, R. de Vries, R.A. Tio, and I.C. van der Horst Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A(2) mass in nondiabetic subjects but not in patients with type 2 diabetes Eur J Clin Invest 41 2011 820 827
29. S. Braschi, D. Masson, G. Rostoker, E. Florentin, A. Athias, and C. Martin Role of lipoprotein-bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome Arterioscler Thromb Vasc Biol 17 1997 2559 2567
30. D.B. Duncan Multiple range and multiple F-tests Biometrics 11 1955 1 42
31. American Diabetes Association Standards of Medical Care 2010 Diabetes Care 33 2010 S30 S32
32. The Accord study group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
33. D. Gavish, E. Leibovitz, I. Shapira, and A. Rubinstein Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety J Intern Med 247 2000 563 569
34. A.M. Wägner, O. Jorba, R. Bonet, J. Ordóñez-Llanos, and A. Pérez Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia J Clin Endocrinol Metab 88 2003 3212 3217
35. B. Zhang, A. Matsunaga, D.L. Rainwater, S. Miura, K. Noda, and H. Nishikawa Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study J Lipid Res 50 2009 1832 1841
36. Z. Qiao, J. Ren, and H. Chen Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits J Int Med Res 37 2009 1029 1037
37. Z.H. Wang, X.L. Liu, M. Zhong, L.P. Zhang, Y.Y. Shang, and X.Y. Hu Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients J Clin Pharmacol 50 2010 311 319